Histogenics

Histogenics is a biotechnology company founded in 2000 and is dedicated to advancing regenerative medicine in the musculoskeletal market. The company's slogan, "Pioneering regenerative solutions for musculoskeletal healing, offering advanced treatments for knee cartilage damage with our innovative platform," reflects its core mission. Histogenics' innovative platform integrates expertise in cell processing, scaffolding, tissue engineering, bioadhesives, and growth factors to deliver solutions for musculoskeletal conditions. The company's leading investigational product, NeoCart®, specifically targets orthopedic applications by offering a novel treatment for cartilage damage in the knee. In October 2018, Histogenics secured a $17.00M Post-IPO Equity investment, signifying continued investor interest in the company's regenerative solutions. While the information about the exact location of its headquarters is not provided, the company's focus on regenerative solutions for musculoskeletal healing positions it within the Biotechnology and Health Care industries.